Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters

Adverse Effects, Drugs Clinical Trials

A listing of Adverse Effects, Drugs medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.


Found (26) clinical trials

Pharmacogenomic Study to Predict Antidepressant Responsiveness in Depressed Patients

The purpose of this study is to determine whether genomic effects on antidepressant response differed by class of drug, whether genomic differences between drug responders and nonresponders predict the response of antidepressant and to construct the prediction model for antidepressant treatment in order to aid to select the their genetically ...

Phase N/A

Patients are needed to participate in a clinical research study to evaluate overdose of drug with toxic effect, Drug-induced Disorder of Liver

Drug-induced liver injury (DILI), especially its idiosyncratic for is often an unpredictable complication of drug therapy. Until now it is very challenging to predict occurrence, severity and outcome of DILI. Previous data provide evidence that cells from peripheral blood may reflect hepatocellular damage (Fannin RD, Hepatology. 2010). Own research could ...

Phase N/A

High-Dose Pulsatile Erlotinib/Gefitinib for Advanced NSCLC Patients After Failure of Standard Dose EGFR-TKIs

To evaluate the efficacy and safety by treating the advanced non small cell lung cancer (NSCLC) patients who have failure of standard dose EGFR-TKIs(Erlotinib or Gefitinib ) with high-dose, pulsatile Erlotinib(450mg every 3 days) or Gefitinib (1000mg every 4 days)


Post-marketing Safety Surveillance of Breviscapine Powder-Injection : a Registry Study

Breviscapine Powder-Injection is a kind of natural compound injection with high purity of Scutellarin-Na (over 98%). It's a popular drug for ischemic diseases, as cerebral ischemic stroke, coronary heart disease or angor pectoris. However, more and more case reports about the adverse drug events of Chinese medicine injections extracted from ...

Phase N/A

National Active Surveillance Network and Pharmacogenomics of Adverse Drug Reactions in Children

CPNDS will identify ADR predictive markers by comparing DNA and plasma samples from patients that suffer ADRs with samples from control populations that are stratified by medication type and age. The GATC will obtain its clinical material for ADR patients mainly, from hospital-based active surveillance network across Canada's major hospitals. ...

Phase N/A

Post-marketing Safety Surveillance of Compound Kuh-seng Injection: a Registry Study

This registry aims to monitor the safety of Compound Kuh-seng Injection and to identify the potential risk factors for the adverse drug reactions. Compound Kuh-seng Injection is a kind of natural compound injection extracted from herbs Kuh-seng (Radix Sophorae Flavescentis) and Rhizoma Heterosmilacis Japonicae.

Phase N/A

Adverse Drug Events at Emergency Department

Emergency departments (EDs) are a crucial element of the health care systems at interface between hospital and communities. The goals of the ED are to make an initial diagnosis and deliver urgent and critical care 24 hour per day and 365 days a year. Also, many Adverse Drug Events (ADEs) ...

Phase N/A

Genetics of QT Prolongation With Antiarrhythmics

Drug-induced long QT syndrome (LQTS), and the subsequent fatal arrhythmia torsade de pointes (TdP), is a major concern with use of a number of medications. Prolongation of the QT interval is the most common cause of withdrawal of medications already on the market, and despite the relatively rarity with non-cardiovascular ...

Phase N/A

Medication Reconciliation Using Electronic Pharmaceutical Record: A Multicenter Study in the Hospitalized Elderly

Context Adverse drug events (ADEs) may occur in community or hospitalized patients. A review of the literature reports an incidence of ADEs varying from 0.1 to 61.4 %. This wide range may be explained by different designs and case-mix in the studies. For instance, the incidence of ADEs is higher ...

Phase N/A

PREemptive Pharmacogenomic Testing for Preventing Adverse Drug REactions

Pre-emptive pharmacogenomic testing will be implemented in clinical sites across seven European countries (United Kingdom, The Netherlands, Austria, Greece, Slovenia, Italy and Spain). The 36-month study is split into two 18-month blocks. The participating countries are randomized to start with either implementing pharmacogenomics guided prescribing or with standard of care ...

Phase N/A